Study of an injectable drug for sleep apnea and obesity
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests an investigational injectable medication (HDM1005) to see if it can improve sleep apnea and help with weight loss in people who are obese and have obstructive sleep apnea but do not use a CPAP machine. The drug is given by injection and compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your body mass index (BMI) is 28 or higher (considered obese).
- You have been diagnosed with obstructive sleep apnea, with a moderate to severe apnea-hypopnea index (AHI) of 15 or more events per hour.
- You are not currently using a CPAP or other positive airway pressure device, and you are not planning to start during the study.
- Your weight has been stable (no more than 5% change) in the last 3 months.
- You do not have diabetes (except gestational diabetes in the past), certain thyroid conditions, or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine (HDM1005) for people who have both obesity and obstructive sleep apnea (where breathing stops during sleep) and who already use a CPAP machine. The goal is to see if the medicine can reduce breathing pauses and improve sleep quality compared to a placebo.
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
This trial tests an injectable medication (HRS9531) to see if it helps people with both obstructive sleep apnea and obesity. It compares the drug to a placebo (no active medicine) to check safety and effectiveness.
This trial is testing an investigational medication (GZR18) to help people with obesity and obstructive sleep apnea (a condition where breathing stops during sleep) lose weight. It is given alongside the usual positive airway pressure (PAP) therapy, which helps keep the airway open during sleep. The goal is to see if the drug can improve weight and possibly sleep apnea symptoms.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
This study tests a new once-a-week injection (called GZR18) to help people with obesity and sleep apnea lose weight and improve their breathing during sleep, without using a CPAP machine. The treatment may help you lose weight and reduce sleep apnea symptoms.
Hear when a new Obstructive Sleep Apnea (OSA) and Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.